6f4edd9f Figure 05
Dexmethylphenidate Hydrochloride Tablet
Product Images NDC 10702-107
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Dexmethylphenidate Hydrochloride (NDC 10702-107). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Kvk-tech, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
6f4edd9f Figure 06
6f4edd9f Figure 07
Chemical Formula Figure 01
Company Logo Figure 04
Table 3 Figure 02
This table presents efficacy results from a study on the treatment of ADHD in pediatric patients aged 6-17 years. The primary efficacy measure was the Teacher SNAP-ADHD Total Score, and the table summarizes the Mean Baseline Score, Mean change from baseline to week 4, and Week 4 Score for the Treatment Group (n=42) and Placebo Group (n=41). The results show a statistically significant difference between the two groups, with the Treatment Group demonstrating greater improvement in symptoms.*
Table 4 Figure 03
This is a summary of the efficacy results from a randomized withdrawal study focusing on attention deficit hyperactivity disorder (ADHD) treatment in pediatric patients aged 6 to 17. The study (Study 2) compares the proportion of treatment failures between the Focalin 5-20mg/day treatment group and placebo. Out of the 35 randomized patients, 6 (17.1%) failed in the Focalin group while 25/40 (62.5%) failed in the placebo group. The Focalin treatment was statistically significantly better than the placebo.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
